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Photothermal therapy (PTT) is a thermal therapy for cancer that uses light-absorbing nanoparticles activated
with a wavelength-matched light source, typically a near infrared laser. Besides triggering tumor cell death, an
additional effect sought during PTT is the activation of an antitumor response from the immune system with the
goal of generating robust and durable treatment outcomes. Over the past few years, we have synthesized
biodegradable Prussian blue nanoparticles (PBNPs), an FDA-approved material, to administer PTT (termed
PBNP-PTT).1 We have also biofunctionalized the nanoparticles with immunological adjuvants (e.g. toll-like
receptor, TLR, agonists)2-4 and administered biofunctionalized PBNP-PTT in combination with immunotherapies
including immune checkpoint inhibitors4,5 and agonistic monoclonal antibodies6 in syngeneic models of
neuroblastoma,1-5,7 melanoma,6 and breast cancer. Through these tumor-specific, mix-and-match combination
therapy approaches, we seek to design immunoengineered therapeutic regimens for cancer that elicit maximum
tumor regression, prevent recurrence, and potentiate effective immunological memory.
In our studies, the PBNPs were synthesized using a one-pot synthesis scheme. The resulting, stable, and
monodisperse PBNPs were then coated with immunological adjuvants (e.g. the TLR agonist PolyIC) using layerby-layer coating schemes (Fig. 1). The biofunctionalized PBNPs were used for PTT at thermal doses that trigger
maximum immunogenic cell death, alone or in combination with immunotherapies in syngeneic, murine models
of cancer. In multiple murine models of neuroblastoma, melanoma, and breast cancer (Fig. 2), our PBNP-PTTbased immunoengineered therapies generated significantly higher complete response, long-term survival,
protection against tumor rechallenge, and robust immunological memory, primarily driven by endogenous T
cells. These findings demonstrate the potential of our PBNP-based immunoengineered therapies as next
generation therapies for cancer.
Figure 1 – Synthesis scheme for
PolyIC-coated PBNPs. PBNPs are
coated, layer-by-layer, first with
polyethyleneimine (PEI) and
subsequently with PolyIC to generate
the PolyIC-PBNP
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Figure 2 – PolyIC-PBNP-PTT improves survival of 4T1 breast cancer, tumor-bearing mice. (a)Schematic
overview of the in vivo study. (b) Maximum tumor temperature measured using a thermal camera every minute
for 10 consecutive minutes. (c) Long-term survival in the various treatment groups post-treatment indicating
maximum survival in the PolyIC-PBNP-PTT groups followed by two boosters of PolyIC-PBNP (*p<0.05,
**p<0.01).
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